Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer

Gynecologic Oncology

Volumn 135, Issue 1, 2014, Pages 58-63

  Verhoef, Viola M J ^a   Heideman, Daniëlle A M ^a   Van Kemenade, Folkert J ^a   Rozendaal, Lawrence ^a   Bosgraaf, Remko P ^b   Hesselink, Albertus T ^a   Bekkers, Ruud L M ^b   Massuger, Leon F A G ^b   Steenbergen, Renske D M ^a   Snijders, Peter J F ^a   Berkhof, Johannes ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical intraepithelial neoplasia; Cervical screening; DNA methylation; HPV genotyping; Human papillomavirus; Self sampling

Indexed keywords

MICRORNA 124; MICRORNA 124 2; UNCLASSIFIED DRUG; MICRORNA; MIRN124 MICRORNA, HUMAN; VIRUS DNA;

ADULT; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; DNA METHYLATION; FEMALE; GENETIC MARKER; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; PRECANCER; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; CERVICAL INTRAEPITHELIAL NEOPLASIA; GENETICS; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; METABOLISM; PATHOLOGY; PROCEDURES; SELF EVALUATION; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DIAGNOSTIC SELF EVALUATION; DNA METHYLATION; DNA, VIRAL; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MICRORNAS; NEOPLASM GRADING; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; UTERINE CERVICAL NEOPLASMS;

EID: 84908007818     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.08.003     Document Type: Article

References (37)

1. M. Arbyn, A.O. Raifu, E. Weiderpass, F. Bray, and A. Anttila Trends of cervical cancer mortality in the member states of the European Union Eur J Cancer 45 2009 2640 2648
2. J. Peto, C. Gilham, O. Fletcher, and F.E. Matthews The cervical cancer epidemic that screening has prevented in the UK Lancet 364 2004 249 256
3. A.B. Bos, M. Rebolj, J.D. Habbema, and M. van Ballegooijen Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands Int J Cancer 119 2006 2372 2375
4. P.J. Snijders, V.M. Verhoef, M. Arbyn, G. Ogilvie, S. Minozzi, and R. Banzi High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening Int J Cancer 132 2013 2223 2236
5. F.H. Zhao, A.K. Lewkowitz, F. Chen, M.J. Lin, S.Y. Hu, and X. Zhang Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method J Natl Cancer Inst 104 2012 178 188
6. E. Lazcano-Ponce, A.T. Lorincz, A. Cruz-Valdez, J. Salmeron, P. Uribe, and E. Velasco-Mondragon Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial Lancet 378 2011 1868 1873
7. Y.L. Qiao, J.W. Sellors, P.S. Eder, Y.P. Bao, J.M. Lim, and F.H. Zhao A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China Lancet Oncol 9 2008 929 936
8. M. Arbyn, F. Verdoodt, P.J. Snijders, V.M. Verhoef, E. Suonio, and L. Dillner Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis Lancet Oncol 15 2014 172 183
9. J. Cuzick, C. Clavel, K.U. Petry, C.J. Meijer, H. Hoyer, and S. Ratnam Overview of the European and North American studies on HPV testing in primary cervical cancer screening Int J Cancer 119 2006 1095 1101
10. G. Ronco, P. Giorgi-Rossi, F. Carozzi, M. Confortini, P.P. Dalla, and M.A. Del Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test J Natl Cancer Inst 100 2008 492 501
11. D.C. Rijkaart, J. Berkhof, F.J. van Kemenade, V.M. Coupe, A.T. Hesselink, and L. Rozendaal Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening Int J Cancer 130 2012 602 610
12. P.E. Castle, M.H. Stoler, T.C. Wright Jr., A. Sharma, T.L. Wright, and C.M. Behrens Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study Lancet Oncol 12 2011 880 890
13. F. Garcia, B. Barker, C. Santos, E.M. Brown, T. Nuno, and A. Giuliano Cross-sectional study of patient- and physician-collected cervical cytology and human papillomavirus Obstet Gynecol 102 2003 266 272
14. A.A. Brink, C.J. Meijer, M.A. Wiegerinck, T.E. Nieboer, R.F. Kruitwagen, and F. van Kemenade High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush J Clin Microbiol 44 2006 2518 2523
15. M.J. Khan, P.E. Castle, A.T. Lorincz, S. Wacholder, M. Sherman, and D.R. Scott The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice J Natl Cancer Inst 97 2005 1072 1079
16. T.C. Wright Jr., M.H. Stoler, C.M. Behrens, R. Apple, T. Derion, and T.L. Wright The ATHENA human papillomavirus study: design, methods, and baseline results Am J Obstet Gynecol 206 2012 46
17. A.T. Hesselink, D.A. Heideman, R.D. Steenbergen, M. Gok, F.J. van Kemenade, and S.M. Wilting Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy Int J Cancer 135 2014 880 886
18. F.X. Bosch, A. Lorincz, N. Munoz, C.J. Meijer, and K.V. Shah The causal relation between human papillomavirus and cervical cancer J Clin Pathol 55 2002 244 265
19. N. Munoz, F.X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, and K.V. Shah Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 2003 518 527
20. A.T. Hesselink, D.A. Heideman, R.D. Steenbergen, V.M. Coupe, R.M. Overmeer, and D. Rijkaart Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women Clin Cancer Res 17 2011 2459 2465
21. N. Wentzensen, M.E. Sherman, M. Schiffman, and S.S. Wang Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science Gynecol Oncol 112 2009 293 299
22. J.J. Eijsink, A. Lendvai, V. Deregowski, H.G. Klip, G. Verpooten, and L. Dehaspe A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients Int J Cancer 130 2012 1861 1869
23. R.M. Overmeer, J.A. Louwers, C.J. Meijer, F.J. van Kemenade, A.T. Hesselink, and N.F. Daalmeijer Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women Int J Cancer 129 2011 2218 2225
24. M. Bierkens, A.T. Hesselink, C.J. Meijer, D.A. Heideman, G.B. Wisman, and A.G. Van Der Zee CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease Int J Cancer 133 2013 1293 1299
25. J.J. Eijsink, N. Yang, A. Lendvai, H.G. Klip, H.H. Volders, and H.J. Buikema Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study Gynecol Oncol 120 2011 280 283
26. V.M. Verhoef, R.P. Bosgraaf, F.J. van Kemenade, L. Rozendaal, D.A. Heideman, and A.T. Hesselink Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial Lancet Oncol 15 2014 315 322
27. V.M. Verhoef, M.G. Dijkstra, R.P. Bosgraaf, A.T. Hesselink, W.J. Melchers, and R.L. Bekkers A second generation cervico-vaginal lavage device shows similar performance as its preceding version with respect to DNA yield and HPV DNA results BMC Womens Health 13 2013 21
28. S. Bulk, F.J. van Kemenade, L. Rozendaal, and C.J. Meijer The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996 J Clin Pathol 57 2004 388 393
29. D.C. Rijkaart, J. Berkhof, L. Rozendaal, F.J. van Kemenade, N.W. Bulkmans, and D.A. Heideman Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial Lancet Oncol 13 2012 78 88
30. M. Casparie, A.T. Tiebosch, G. Burger, H. Blauwgeers, A. van de Pol, and J.H. van Krieken Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive Cell Oncol 29 2007 19 24
31. M. Schmitt, I.G. Bravo, P.J. Snijders, L. Gissmann, M. Pawlita, and T. Waterboer Bead-based multiplex genotyping of human papillomaviruses J Clin Microbiol 44 2006 504 512
32. S.M. Wilting, R.A. van Boerdonk, F.E. Henken, C.J. Meijer, B. Diosdado, and G.A. Meijer Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer Mol Cancer 9 2010 167
33. M. Dijkstra, D. van Niekerk, D. Rijkaart, F.J. van Kemenade, D.A. Heideman, and P. Snijders Primary hrHPV DNA testing in Cervical Cancer screening: how to manage screen positive women? A POBASCAM Trial sub study Cancer Epidemiol Biomarkers Prev 23 2013 55 63
34. J. Cuzick, C. Clavel, K.U. Petry, C.J. Meijer, H. Hoyer, and S. Ratnam Overview of the European and North American studies on HPV testing in primary cervical cancer screening Int J Cancer 119 2006 1095 1101
35. D.C. Rijkaart, J. Berkhof, L. Rozendaal, F.J. van Kemenade, N.W. Bulkmans, and D.A. Heideman Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial Lancet Oncol 13 2012 78 88
36. R.P. Bosgraaf, V.M. Verhoef, L.F. Massuger, A.G. Siebers, J. Bulten, and G.M. de Kuyper-de Ridder Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30,130 women not attending cervical screening Int J Cancer 2014 10.1002/ijc.29026 [Epub ahead of print]
37. M. Gok, D.A. Heideman, F.J. van Kemenade, A.L. de Vries, J. Berkhof, and L. Rozendaal Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: characteristics of the responders Eur J Cancer 48 2011 1799 1808